Liquidia Q3 net loss $15.8M; YUTREPIA PH-ILD PDUFA Jan 24, 2024

Liquidia Corp

2023-Q3 EPS reported -$0.79 revenue$12,957,000

Net loss $15.8M ($0.24/sh) vs $9.1M ($0.14/sh) in Q3 2022; cash $76.2M vs $93.3M at year-end.
Revenue $3.7M (+15% YoY) from Sandoz treprostinil injection promotion agreement.
R&D spend up 65% to $7.4M on YUTREPIA pre-launch; G&A up 57% to $10.6M on litigation and commercial prep.
PDUFA date for PH-ILD label expansion Jan 24, 2024; final approval delayed to Mar 31, 2024 due to Tyvaso exclusivity.
Oral arguments in '793 patent appeal set for Dec 4, 2023; CAFC ruling could enable final YUTREPIA approval.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Liquidia Corp reported the third quarter ended September 30, 2023 results: revenue $3.7 million.

Period: the third quarter ended September 30, 2023
Revenue: $3.7 million
Result: reported results

Exact text from the filing

for PAH and PH-ILD. Third Quarter 2023 Financial Results Cash totaled $76.2 million as of September 30, 2023, compared to $93.3 million as of December 31, 2022. Revenue was $3.7 million for the three months ended September 30, 2023, compared to $3.2 million for the three months ended September 30, 2022. Revenue related primarily to the promotion agreement

View on SEC.gov

700 earnings releases filed in the last 30 days. Browse all earnings releases →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-114983

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.